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Objectives: There are a number of blockbuster monoclonal antibodies on the market used for the 2 
treatment of a variety of diseases. Although the formulation of many antibodies is achieved in 3 
 ?platform ? formulations, some are difficult to formulate that can result in an inability to develop a 4 
finished drug product. Further, a large number of antibody inspired or based molecules are now 5 
being developed and assessed for biotherapeutic purposes and less is understood around the 6 
required active protein drug concentrations, excipients and additives required in final product 7 
formulations.  8 
Results: We investigated the effect of formulation variables (pH, buffer composition, glycine and 9 
NaCl concentration, time and temperature of accelerated stability studies) on antibody 10 
solubility/aggregation and activity using a Plackett-Burman Experimental Design approach. We 11 
then used the findings from this study and applied these to the formulation of a single chain 12 
variable fragment (ScFv) molecule. Our data shows that prediction of ScFc stability from a model 13 
monoclonal antibody could be achieved although further formulation optimization was required. 14 
Mass spectrometry analysis confirmed changes to the mass and hence authenticity of both the 15 
model antibody and ScFv under formulation conditions that did not provide appropriate 16 
conditions for protection of the molecules. 17 
Conclusions: We report and discuss on the role of the different formulation conditions on 18 
maintaining protein integrity and show using mass spectrometry that protein integrity is 19 
compromised under particular conditions. The implications for predicting successful formulations 20 
for protein molecules is discussed and how antibody formulations could be used to predict 21 
formulation components for novel antibody based molecules. 22 
 23 
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Monoclonal antibody (mAb) based drugs have been a huge success in the clinic and there are 2 
many more in development for the treatment of diseases including cancer and rheumatoid 3 
arthritis (Ivanov et al 2009; Ford et al ; Kurata et al; Wang et al 2007; Goi et al ). Although 4 
recombinant proteins can be successfully formulated and stabilised by lyophilisation (Smales et al 5 
2002; Povey et al 2009), most of the mAb products currently in the clinic are administered by 6 
intravenous infusion (Zhu et al 2014). Due to the ŝŶũĞĐƚŝŽŶǀŽůƵŵĞƚŚĂƚŝƐďĞƐƚĨŽƌĂĚŵŝŶŝƐƚƌĂƚŝŽŶ ?ч7 
1.5 ml), ĂŶĚ ƚŚĞ ůĂƌŐĞ ĚŽƐĞ ƌĞƋƵŝƌĞŵĞŶƚƐ ĨŽƌ ŵŽƐƚ ĂŶƚŝďŽĚǇ ƚƌĞĂƚŵĞŶƚƐ  ?ш ? ? ?-400 mg per 8 
treatment), this generally means that antibodies must be formulated as high concentration 9 
solutions (Dani et al 2007). The development of such high concentration formulations can be 10 
challenging due to the increased potential for inter-molecular interactions and macromolecular 11 
 ?ĐƌŽǁĚŝŶŐ ? ŝŶ ƐŽůƵƚŝŽŶ ? ĂŶĚ ĐŽŶĐĞŶƚƌĂƚŝŽŶ-dependent aggregation (Dani et al 2007). Such 12 
deleterious effects can lead to issues with stability, activity, pharmacokinetics, potentially patient 13 
safety, and practical issues in delivery (Harn et al 2007). 14 
The stability of a mAb may be compromised throughout all stages of production and 15 
manufacturing by factors including shear, presence of deleterious host cell proteins, pH, buffer 16 
composition and temperature. The most common issue associated with instability is aggregation, 17 
which is more prominent in high protein concentration solutions (Dani et al 2007; Demeule et al 18 
2007a; Demeule et al 2007b; Harn et al 2007). Beyond the practical issues of drug delivery, 19 
aggregation can also reduce the efficacy of the protein (Cudd et al 1995) and result in toxic effects 20 
and potentially increased immunogenicity (Hermeling et al 2004). Aggregates are usually formed 21 
after storage at extreme temperatures and pH values that induce protein unfolding and increase 22 
the intermolecular interactions of hydrophobic regions which lead to an increase in aggregation 23 
events (Carpenter et al 1999; Liu et al 2008), however at high protein concentrations such events 24 
can be observed in the absence of extreme temperature or pH when formulation conditions are 25 
unfavourable.  26 
Although many mAb based drugs have been produced and used as delivery vehicles for 27 
other therapeutic molecules, and the formulation of many IgGs is undertaken in platform 28 
formulations, there remain cases where it is difficult to successfully formulate particular mAb 29 
molecules resulting in an inability to develop a finished drug product. Further, molecules that are 30 
constituted of domains or sections of antibody have now also been developed and require 31 
different active protein drug concentrations, excipients and additives. Formulation development 32 
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of recombinant proteins is usually undertaken using a screening approach whereby excipients and 1 
additives are changed in order to find a combination that provides the desired stability profile 2 
(Almeida et al 2017; Gourbatsi et al 2016). Here, we report on the investigation of the effect of 3 
different formulations variables on protein integrity as measured by aggregation, activity, 4 
structural and chemical stability using a model mAb IgG4 molecule. We then ask the question as to 5 
whether the mAb information could be applied to the design of a formulation of a model single 6 
chain Fv (ScFv) molecule. From the findings, we discuss how an understanding of the model mAb 7 
and ScFv formulation requirements can be extrapolated to aid in further formulation design of 8 
^Đ&ǀ ?Ɛ.  9 
 10 
MATERIALS AND METHODS 11 
Reagents. All reagents were purchased from Sigma-Aldrich (Dorset, UK) and were of analytical 12 
grade or higher. The model mAb was an IgG4 lambda molecule that had been produced in Chinese 13 
hamster ovary (CHO) cells, purified and formulated in a storage buffer of 50 mM sodium acetate 14 
(pH 5.5).  15 
Plackett-Burman Design of Experiments. The effect of formulation variables (pH, buffer 16 
composition, glycine and NaCl concentration, time and temperature of accelerated stability 17 
studies) on antibody solubility/aggregation and activity were investigated. In order to investigate 18 
the effect of these variables on protein aggregation and stability whilst limiting the potential 19 
number of conditions to investigate, a Plackett-Burman Experimental Design was implemented 20 
(Supplementary Tables 1 and 2) in a manner to that previously described (Gourbatsi et al 2016). 21 
Triplicate samples were investigated for each formulation and the mean of all analyses calculated. 22 
A two-tailed t-test was used to compare sample means i.e. the low and high values of each 23 
variable.  24 
Dialysis, freeze-drying and resuspension of samples in test formulations. In order to remove any 25 
existing buffer salts present, protein samples were initially dialysed against the appropriate 26 
formulation buffer. The concentration of antibody in solution was monitored before and after 27 
storage by measuring the absorbance at 280 nm using a NanoDrop ND-1000 spectrophotometer. 28 
After storage under the appropriate conditions, samples were centrifuged at 200 X g for 4 min in a 29 
benchtop 5702 centrifuge (Eppendorf UK). The pellets were carefully separated from the 30 
supernatants and resolubilized in 100 µl 8 M urea, 0.25 M Tris-HCl (pH 8.75), 1 mM EDTA. The 31 
samples were shaken for several minutes and centrifuged for a further 4 min and then the 32 
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concentration determined by A280 measurement. A visual record of samples before and after 1 
storage was also recorded using a Nikon D70 camera. 2 
SDS-PAGE analysis. Standard SDS-PAGE was undertaken under non-reducing conditions using a 3 
7.5% acrylamide resolving gel and for reduced samples using a 12% acrylamide resolving gel. 4 
Samples were adjusted to 1 mg/ml for analysis. The relative quantification of bands was 5 
undertaken using the freeware ImageJ software (https://imagej.nih.gov/ij/). 6 
Equilibrium denaturation studies. The stability of the model mAb in high concentration 7 
formulations was studied by denaturation analysis using guanidine hydrochloride as the 8 
denaturant using the method previously described by Williamson et al. (1994). 9 
Fluorescence spectroscopy. A Cary Eclipse fluorescence spectophotometer (Varian Ltd, Oxford, 10 
U.K.) was used for the collection of fluorescence data. Suspensions of 1 mg/ml (low protein 11 
concentration) and 90 mg/ml (high protein concentrations) were examined. The excitation 12 
wavelength was 295 nm and the emission was measured between 300 to 400 nm at 900 V with 10 13 
nm slits. The excitation filter was set to auto and the detector voltage was 900 V. Measurements 14 
were taken from an average of four scan passes. For data analysis, the graphs were plotted in 15 
ǆĐĞůĂŶĚƚŚĞʄmax determined. The data was normalized by plotting the ratio of the intensity over 16 
maximum wavelength intensity. 17 
Size-exclusion chromatography-high performance liquid chromatography (SEC-HPLC). The model 18 
mAb was analysed on a Waters 600 series HPLC associated with a Waters 486 tunable absorbance 19 
detector and absorbance monitored Ăƚ  ? ? ? Ŷŵ ? ^ĂŵƉůĞƐ ǁĞƌĞ ĚŝůƵƚĞĚ ƚŽ  ? ŵŐ ?ŵů ĂŶĚ  ? ? ʅů20 
injected onto a pre-equilibrated TSK-Gel 3000SWxl column with 0.2 M sodium phosphate buffer 21 
pH 7.5. For generation of a standard curve, dilutions of known concentrations of mAb were 22 
prepared in 0.2 M sodium phosphate buffer pH 7.5. A constant flow rate (1.0 ml/min) was used for 23 
all runs.  24 
Data analysis. All data was analysed using the Sequential Design of Expert tool (EasyStats, DX7, 25 
Version 7.1.6, Stat-Ease® Inc., Minneapolis, U.S.A.) to investigate and correlate the effect of 26 
individual variables and predict the best formulation conditions for long term storage at 4°C and 27 
25°C. The criteria used for selection of the best formulation conditions were to optimize pH, buffer 28 
composition, glycine and NaCl concentrations to maximise the concentration of mAb in solution, 29 
and the visual appearance to be minimized (0 was scored for a clear solution and 1 was scored for 30 




Heavy and light chain analysis of the model mAb by mass spectrometry. Mass spectrometry 1 
analysis was undertaken as previously described (Gourbatsi et al 2016).  2 
Analysis of a model single chain fragment variable region (ScFv). A single chain fragment variable 3 
region (ScFv) was provided by MedImmune in PBS (pH 7.3). The fragment was dialysed against 4 
dH2O, freeze-dried and then 0.61 mM samples prepared in appropriate formulations based upon 5 
date collected from the model mAb analysis. Samples were analysed as described for the model 6 
mAb.  7 
 8 
RESULTS 9 
Determination of model mAb solubility with varying formulation. Following standard industrial 10 
procedure, an initial impression as to how different formulations affected mAb stability was 11 
undertaken visually against an intense light background. Visual analysis indicated that 12 
formulations 1, 3, 8 and 12 (Supplementary Table S2) resulted in the majority of mAb precipitating 13 
out to form a gel like aggregate (data not shown). The effect of formulation variables on initial 14 
protein solubility and any further effect during accelerated storage studies at raised temperature 15 
were then investigated by measuring the absorbance at 280 nm immediately after formulation 16 
and then again after the relevant storage time (Supplementary Table S1). Changes in the 17 
concentration as determined by A280 were calculated and the results and statistical analysis are 18 
shown in Supplementary Tables S3 and S4 respectively. From the A280 analysis and two tailed t-test 19 
statistical testing there was not a single factor identified as being the statistically significant factor 20 
impacting upon concentration remaining in solution upon formulation. However, after storage the 21 
most significant variable factors were, not surprisingly, protein concentration and the temperature 22 
of storage. Of the other variables, although none of these was above the 80% significance level, 23 
these generally had more of an effect initially upon formulation than after storage (Supplementary 24 
Table S4). The data did show, along with the visual data, that several formulations were 25 
particularly unsuitable (1, 3, 8, 12) and although all of these were subjected to the high 26 
temperature condition, other high temperature formulations were not adversely affected. Of the 27 
high protein concentration samples, formulations 4, 9 and 10 did not precipitate compared to high 28 
concentration samples 1, 8 and 12. However, formulation 4 was at low temperature for the 29 
maximum time investigated, formulation 9 and 10 at low temperature whilst formulations 1 and 30 
12 were stored for the maximum time investigated at maximum temperature and formulation 8 at 31 
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maximum temperature for 2 h. This suggests that storage temperature was the key variable in the 1 
initial study. 2 
SDS-PAGE analysis of MAb samples in the different formulations. SDS-PAGE analysis of all 3 
supernatants and pellets of the mAb samples was undertaken in order to investigate changes in 4 
protein aggregation (precipitate versus supernatant) (Figure 1). Where it was necessary to 5 
resolubilized pellets this was undertaken in 8 M urea solution (formulations 1, 3, 8, and 12) and for 6 
these samples supernatant analysis was not possible. For the mAb sample in formulation 12, not 7 
all protein was initially in solution and thus the precipitate observed after storage was not due to 8 
the temperature of storage. Differences in the banding pattern in the non-reduced SDS PAGE gel 9 
after storage of formulations 3R (where R stands for resolubilized pellet), 6 and 7 compared to the 10 
standard indicates that these formulations and conditions had an impact upon the mAb sample 11 
that was not evident from the A280 measurements alone (Figure 1A). Further, upon reduced SDS-12 
PAGE analysis, the samples in formulations 6 and 11 showed a different banding profile from the 13 
standard sample (Figure 1B).  14 
Determination of soluble aggregates in mAb formulations by size exclusion chromatography 15 
(HPLC-SEC). Quantitative analysis of the amount of soluble aggregate in the different formulated 16 
samples was undertaken by size exclusion chromatography and the area under the different peaks 17 
representing aggregates of different size determined. Across the samples four major peaks/areas 18 
were observed (Figure 2). These are labelled as peaks I, II, III and IV in figure 2E where peak III 19 
corresponds to the fully assembled and intact mAb monomer. Two peaks eluted earlier than the 20 
standard corresponding to higher molecular weight aggregates (I and II at 5-6 mins and 6-7 mins 21 
respectively, Figure 2) and one later eluting peak (IV 8-9 mins, Figure 2) that was smaller than the 22 
monomer and is likely due to disassembled mAb. A summary of the integration of the area under 23 
each peak as a percentage of the total area for each sample is depicted in Figure 3. The analysis of 24 
samples in formulation 2 showed clear evidence of higher molecular weight aggregates as well as 25 
disassembled antibody material despite the fact that other methods of analysis had shown no 26 
effect of this formulation on stability. Resolubilised material from formulation 8 also revealed the 27 
presence of higher order aggregate (Figure 2). The amount of each peak in the HPLC-SEC analysis 28 
as a percentage of the total peak area is reported in Figure 2. In all cases more aggregate or 29 
disassembed material was present in the formulated samples after storage than in the standard 30 
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samples. High molecular weight aggregate was observed after storage of mAb in low protein 1 
concentrations and high protein concentration formulations. 2 
mAb stability in different formulations as determined by fluorescence and guanidine 3 
hydrochloride denaturation studies. In order to determine whether any large structural changes 4 
were observed in the different mAb high protein concentration formulations, fluorescence studies 5 
were undertaken. Figure 4 ƐŚŽǁƐ ƚŚĞʄmax of the mAb samples in the different formulations, an 6 
indication of how accessible tryptophan residues are to the solvent. The fluorescence curves show 7 
ƚŚĂƚƚŚĞƌĞǁĂƐĂƐŚŝĨƚŝŶƚŚĞŽďƐĞƌǀĞĚʄmax after storage in formulation 12 and smaller shifts after 8 
storage in formulations 1, 8 and 4 (Figure 4a). A shiĨƚ ƚŽĂŚŝŐŚĞƌʄmax is an indication of protein 9 
ƵŶĨŽůĚŝŶŐ ŝŶ ƚŚĞƐĞ ĨŽƌŵƵůĂƚŝŽŶƐ ? dŚĞƌĞ ǁĂƐ ŶŽ ĐŚĂŶŐĞ ŝŶƚŚĞ ŽďƐĞƌǀĞĚ ʄmax for samples in 10 
formulation 10 and the fluorescence data for such samples was almost identical to the standard 11 
sample (Figure 4a). In addition, we undertook guanidine hydrochloride denaturation of the high 12 
concentration model mAb that had been stored under different formulation conditions 13 
(formulations 4, 9 and 10) to further investigate the conformational stability under the different 14 
conditions. The denaturation of the mAb with increasing guanidine hydrochloride concentrations 15 
resulted in a small shift in the fluorescence emission maximum when intrinsic fluorescence was 16 
excited at 280 nm (Figure 4b). The curves all showed one phase of unfolding with the denaturation 17 
midpoint occurring at approximately 1.75 M guanidine hydrochloride (Figure 4b). All samples will 18 
therefore have more-or-ůĞƐƐ ƚŚĞ ƐĂŵĞ ȴ' ?  ?ƐƚĂŶĚĂƌĚ ĨƌĞĞ ĞŶĞƌŐǇ ĐŚĂnge between native and 19 
denatured states) and little or no difference in their stability as determined by standard 20 
denaturation analysis.  21 
ESI-MS analysis of reduced mAb under different formulation conditions for the presence of 22 
protein modifications. For mass spectrometry analysis, mAb was initially subjected to reduction 23 
and alkylation to allow intact analysis of the heavy and light chains. The major heavy chain (HC) 24 
and light chain (LC) masses and relative abundance of each are reported in Figure 5. The major HC 25 
mass observed in each sample was at approximately 51171 Da, which corresponds to the expected 26 
mass of the mAb heavy chain. A number of other heavy chain species were also present in the 27 
standard and formulated samples (Figure 5A). Analysis of samples from the different formulations 28 
also revealed HC mass peaks not observed in the standard sample, indicative of either loss or gain 29 
of mass and therefore protein modification. For example, the HC spectra of samples in formulation 30 
10 contained a peak of mass 47372 Da, a mass loss of 3797 Da. For the light chain analysis (Figure 31 
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5B), the major peak observed had a mass of 22899 Da in the standard sample and a number of 1 
higher mass species were also present. As in the case of the heavy chain analyses, samples 2 
formulated in formulations 4, 9 or 10 had species of light chain with a different mass to that 3 
observed in the control, indicative of protein modification(s) (Figure 5B). 4 
Do mAb samples stored under different formulation conditions have different activity? To 5 
determine whether there was any effect on the activity of the model mAb in the high 6 
concentration formulations, potency assays were undertaken. Due to the limited amount of 7 
antibody in solution after storage in formulations 1, 8 and 12, potency assay measurements were 8 
only undertaken after storage in formulations 4, 9 and 10. The resulting dose response curves are 9 
shown in Figure 6. The data shown reveals that there was no significant change in the activity of 10 
the antibody in formulation conditions 4, 9 and 10 compared to the control sample. Thus, under 11 
the conditions and formulations of 4, 9 and 10, mAb samples maintained their physical and 12 
structural stability and antibody potency/activity.  13 
Statistical analysis of all mAb data. Design-Expert 7.1.6 was used to statistically analyse and 14 
correlate the data from all mAb samples and formulations studied here to identify any variable(s) 15 
impacting on the stability and integrity of the mAb. Temperature, as expected, was found to be 16 
the most important factor of all the responses recorded (solubility, visual appearance, SDS-PAGE 17 
analysis, fluorescence, reduced heavy and light chain mass spectrometry analysis and potency of 18 
the mAb) after accelerated storage in the appropriate conditions (Table 1). For some of the 19 
responses, the effect of temperature was extremely prominent such as solubility (97.2% increase 20 
in protein precipitation as the temperature increases), heavy and light chain mass changes (99.9% 21 
change in the mass as the temperature increases), aggregation (41.1% change in band intensity as 22 
the temperature increases) and potency (43.1% decrease in the activity as the temperature 23 
increases) (Table 1). Buffer concentration was the next most influential factor affecting the 24 
presence of non-covalent aggregates as indicated by structural stability fluorescence analysis 25 
(Table 1). From the data generated, Design Expert was used to predict the formulation condition 26 
to be the most appropriate for maintaining the mAb protein integrity at 4 and 25°C and this is 27 
reported in Table 2.  28 
The influence of buffer concentration on a model antibody single chain fragment (ScFv). The 29 
effect of buffer concentration on the stability of an antibody single chain fragment from a variable 30 
region (ScFv) was undertaken. The initial formulation used was that based upon the results 31 
10 
 
generated with the model intact mAb and consisted of 250 mM sodium acetate, 0.2 M NaCl and 1 
0.13 M glycine at pH 6.3 and filtered and stored at 4°C and is hence forth referred to as 2 
formulation A. Buffer (sodium acetate) concentrations of 10, 100, 250 and 500 mM were 3 
investigated (with NaCl, glycine and pH kept constant), with ScFV samples formulated in the 4 
varying buffer concentrations and the absorbance at 280 nm and fluorescence profiles of the 5 
resulting ScFv solutions generated after 1 week of storage at 37°C investigated. The ScFv fragment 6 
was soluble in the high buffer concentration formulation (500 mM), but became more insoluble as 7 
the buffer concentration was lowered (10 and 100 mM) and in PBS (Table 3). After a week of 8 
storage at 37°C, the 500 mM buffer concentration formulation maintained the ScFv in solution as 9 
determined by visual analysis while the remaining buffer concentrations did not appear to 10 
deteriorate upon storage any further than observed upon formulation (Table 3). Despite the small 11 
precipitate observed in the PBS, 10 and 250 mM buffer concentration formulations, there were no 12 
large apparent structural changes as determined from tŚĞĨůƵŽƌĞƐĐĞŶĐĞĐƵƌǀĞƐĂŶĚƚŚĞʄmax values 13 
(data not shown). Mass spectrometry analysis of the material from the 100, 250 and 500 mM 14 
samples revealed no major mass changes compared to the control sample (Figure 7). In the 15 
resolubilised pellets of the PBS and 10 mM buffer concentration formulations, the most abundant 16 
mass peaks upon mass spectrometry analysis were twice the expected mass of the protein. It is 17 
likely that dimerization had occurred during storage under these conditions (Figure 7). Other mass 18 
peaks were also observed that were not in the control sample (Figure 7). 19 
 20 
Discussion 21 
A potential issue in developing high protein concentration formulations is protein aggregation that 22 
compromises quality control and biological activity, whilst the administration of such aggregates 23 
can lead to immune-related adverse effects (Harn et al 2007; Shire et al 2004; Kameoka et al 24 
2007). The effect of different formulations variables including protein concentration, pH, buffer 25 
composition, time of storage, storage, temperature, glycine and salt (NaCl) concentration was 26 
therefore investigated on a model mAb. Visual analysis showed that the antibody precipitated out 27 
of solution after storage in formulations 1, 8 and 12 with the most significant factor in terms of 28 
accelerating aggregation, unsurprisingly, being temperature. The impact of temperature in 29 
promoting aggregation events for monoclonal antibodies (and proteins in general) has been well 30 
documented (e.g. Cleland et al 2001; Chen et al 2003; Breen et al 2001). At elevated temperatures, 31 
proteins can partial/completely unfold and for this reason storage temperature is set well below 32 
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the thermal melting for long term stability at 2-8°C (Perico et al 2008). However, temperature is 1 
used during formulation studies to accelerate stability studies and identity formulations that are 2 
less stable, or in this case formulation components. 3 
The protein concentrations in solution were determined in the different formulations 4 
spectrophotometrically at 280 nm before and after storage and statistical analysis was then 5 
applied to the results to identify the variables in terms of aggregation that appeared most 6 
significant. This analysis showed that protein concentration and temperature of storage were 7 
statistically significant with respect to changes in protein concentration. Much work has been 8 
undertaken into this area, for example a study by Perico et al. using an IgG2 monoclonal antibody 9 
demonstrated that the aggregation of this antibody was temperature dependent. This finding 10 
agrees with the analysis here where temperature positively impacted upon the precipitation of 11 
mAb. In particular, under storage conditions of 2-8°C at pH 4.0 there was minimal aggregation 12 
while at elevated temperatures (37°C) the acidic formulations lead to the presence and detection 13 
of high order aggregates. Ejima et al. did not detect a significant increase in aggregation of a 14 
recombinant humanized IgG4 after storage at pH 2.7 and 3.5 at 4°C (Ejima et al 2007) in 15 
agreement with the data presented here where after storage in formulation 4 at pH 4.0 and 4°C 16 
there was no evidence of aggregation based on the A280 measurements, SDS-PAGE or SEC-HPLC 17 
analysis. Thus, low pH alone was not enough to destabilize the antibody. On the other hand, after 18 
storage in formulation 8 at pH 4.0 at elevated temperature (55°C) there was a significant increase 19 
in aggregation events. This agrees with others who have reported the formation of aggregates of a 20 
chimeric monoclonal antibody at pH values below 5 at 60°C (Paborji et al 1994). However, Kuetzo 21 
et al. reported an increase in aggregation at decreased pH of an IgG2 monoclonal antibody during 22 
freeze-thawing after storage at 4°C for up to 6 weeks, and moreover, that the aggregation was 23 
most prevalent at pH 3 and 4 (Kueltzo et al 2008). This contrasts with the data presented here 24 
where formulation 4 is very similar to those in the report by Kuetzo et al but minimal aggregation 25 
of the MAb in this formulation was observed. In a further study two mouse monoclonal antibodies 26 
were stored at 37°C, pH 3 and pH 4, and at 4°C, pH 3.0 and insoluble aggregates were observed 27 
(Jiskoot et al 1990). All of these studies demonstrate the importance of temperature in the 28 
formation of aggregates, especially at low pH, but importantly the different behaviour of different 29 
antibodies and the fact this can be prevented by manipulating formulation conditions.  30 
The presence of non-covalent and covalent aggregates in solution was investigated by 31 
reduced and non-reduced SDS-PAGE. Unfortunately, analysis of the aggregates in high 32 
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concentration formulations where changes were observed in solution was difficult due to the 1 
amount of aggregation. As a result, the precipitate was resolubilized with 8 M Urea/Tris/EDTA, but 2 
this can disrupt the aggregates present and give misleading results. This method was successful for 3 
analysis of formulation 8 where less precipitate was observed and in the subsequent SEC analysis 4 
high molecular weight aggregates were observed. Surprisingly, in the low mAb concentration 5 
formulation 2, the same high molecular weight aggregates were observed and a smaller molecular 6 
weight peak that corresponds to disassembled antibody. The temperature of storage in this 7 
formulation was high (55°C) and this might explain the formation of aggregates. These data show 8 
that even in a clear solution aggregates can be present. Long term storage of such samples could 9 
result in the early aggregate material leading to further aggregates or fibril formation and gelation 10 
with time as has been previously described (Demeule et al 2007a; Demeule et al 2007b).  11 
Protein aggregation usually involves structural and conformational changes to the protein 12 
(Demeule et al 2007a; Demeule et al 2007b). The structural integrity of the model mAb here after 13 
storage in high concentration formulations was therefore investigated by fluorescence analysis. 14 
dŚĞʄŵĂǆĐƵƌǀĞƐƌĞǀĞĂůĞĚƚŚĂƚƚŚĞmAb in majority of high concentration formulations remained 15 
folded although in formulations 1, 8 and 12 that had high storage temperature (55°C) there was a 16 
ƐŚŝĨƚŝŶʄmax to higher values indicating structural change and unfolding. This red shift indicates that 17 
there are local changes in the environment of tryptophan, tyrosine and phenylalanine residues 18 
and suggests that there may be a decrease in the hydrophobicity around these residues i.e. local 19 
environment around tryptophan molecules is more hydrophilic.  20 
The conformational stability of the model mAb after storage in different formulations was 21 
also investigated by guanidine hydrochloride denaturation studies ? dŚĞ ĐŚĂŶŐĞ ŝŶ ƚŚĞ ʄmax was 22 
used to follow the denaturation of the protein with increasing guanidine concentrations 23 
(Williamson et al, 1994). Due to limitations in amount of sample, the analysis was only carried out 24 
for the high concentration formulations 4, 9 and 10. Previous analysis of these formulations 25 
showed no or minimal evidence of aggregation and a single-state unfolding was observed for the 26 
denaturation curves. Little difference in the concentration of guanidine required to initiate and 27 
complete the unfolding between samples in the different formulations was observed, suggesting 28 
that tertiary structure stability was more-or-less the same in all samples investigated. The potency 29 
of these samples was also investigated and statistical analysis suggested there was a significant 30 
difference in the potency of the material from these formulations.  31 
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There are now a number of different antibody formats on the market and in development, 1 
including single chain fragments from variable regions (ScFv, ~20-30 Da). These smaller molecules 2 
can also have stability issues, particularly due to the absence of sections of the constant region of 3 
the light or heavy chain resulting in the exposure of hydrophobic side chains (Worn et al 1999; 4 
Barthelemy et al 2008). Therefore, we investigated the impact of buffer concentration and 5 
composition, as in the case of the model mAb, on a model ScFv. In contrast to the full length mAb, 6 
the fragment did not easily go into solution at 10 mM buffer concentration or in PBS and after 1 7 
week of storage at 37°C there was much insoluble material present. The best buffer concentration 8 
formulation for solubility of the ScFv of those investigated was that at a concentration of 500 mM, 9 
where the fragment went easily into solution and remained so after the appropriate storage. A 10 
possible explanation might be that at this concentration the fragment had reached its isotonicity 11 
(where the solute, in this case the ScFv, concentration is the same as the concentration of the 12 
solution surrounding it). Changes in the overall charge of the fragment that could result in an 13 
increase/decrease of the hydrophobicity might be another factor. Regardless, the work here 14 
demonstrates that potency may not necessarily be impacted by modifications (as determined by 15 
mass spectrometry) of a model mAb and that despite the large amount of work undertaken to 16 
further our understanding of how formulation conditions can impact upon mAb and general 17 
ƉƌŽƚĞŝŶ ƐƚĂďŝůŝƚǇ ? ƚŚĞ ƵƐĞ ŽĨ  ?ƉůĂƚĨŽƌŵ ? ĨŽƌŵƵůĂƚŝŽŶ ďĞĞŶ ĂĚŽƉƚĞĚ ĂĐƌŽƐƐ ƚŚĞ ŝŶĚƵƐƚƌǇ ? ŝƚ ŝƐ Ɛƚŝll 18 
necessary to screen excipients and formulations to identify appropriate formulations for 19 
biotherapeutics and prediction of formulation performance remains a challenging area. 20 
 21 
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Table 1: Analysis to determine the significant variables for the measured responses on mAb after 1 
storage in the different Plackett-Burman high (1, 4, 8, 9, 10 and 12) protein concentration 2 
formulations.  3 
 4 
 5 
  6 
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Table 2: Predicted most appropriate formulation for the maintenance of the model mAb integrity 1 
based on the data generated and reported previously for high protein concentration formulations 2 











(mg/ml) NaCl (M) Desirability 
1.04 6.3 250 4 20.0 0.19 0.96 






Table 3: ScFv visual appearance, precipitation and fluorescence analysis before and after a week of 9 
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Figure Legends 1 
Figure 1: (A) 7.5% non-reduced SDS-PAGE analysis of mAb samples in formulations 1-12, (B) 12% 2 
SDS-PAGE analysis of reduced mAb samples in formulations 1-12. Key: R stands for resolubilized 3 
sample in 8 M urea solution, Std is the standard mAb before formulation.  4 
 5 
Figure 2: Size exclusion chromatography analysis of mAb samples after incubation in various 6 
formulations. (A) standard antibody, (B) formulation 1R, (C) formulation 2, (D) formulation 4, (E) 7 
formulation 8R, (F) formulation 9, (G) formulation 10, (H) formulation 12R. The chromatograph 8 
shown of formulation 1R (B) and 12R (H) shows that there was only a very small amount of protein 9 
in solution. Key: R stands for resolubilized sample in 8 M urea solution.  10 
 11 
Figure 3: The % of each of the four major peaks observed by SEC-HPLC analysis of mAb samples 12 
in different formulations 1-12. RES = resolubilized sample in 8 M urea solution. All values 13 
represent the average of three independent experiments (n=3). 14 
 15 
Figure 4. (A) Fluorescence curves of high concentration mAb samples in formulations 1, 4, 8, 9, 16 
10 and 12 after incubation along with a standard MAb sample or comparison (n=3). The 17 
wavelength at which maximum intensity was observed was approximately 336 nm for all samples 18 
ĞǆĐĞƉƚĨŽƌŵƵůĂƚŝŽŶ ? ? ?ĂŶĚ ? ?ǁŚĞƌĞďǇƚŚĞʄmax was shifted to 344, 339 and 346 nm respectively. 19 
(B) Denaturation curves for mAb in standard solution PBS, mAb in Formulation 4, mAb in 20 
formulation 9, mAb in formulation 10.  21 
 22 
Figure 5: (A) Heavy (HC) and (B) Light chain (LC) mass analysis of mAb samples after incubation in 23 
high concentration formulations 4, 9 and 10 by ESI-MS. The figure shows the abundance of each 24 
peak as a percentage of the most abundant peak which was assigned a value of 100%. 25 
 26 
Figure 6: Dose response curves for the mAb in formulations 4, 9 and 10. (A) mAb in formulation 4 27 
(B), mAb in formulation 9 and (C) mAb in formulation 10. The table shows the reference potency 28 
to the mAb STD. There was no significant change in the activity of the mAb after incubation in 29 
these formulations although in formulation 4 the potency was slightly elevated and in formulation 30 
10 slightly reduced. 31 
 32 
Figure 7: Mass analysis of ScFv samples after incubation in PBS and 100 mM, 250 mM and 500 33 
mM buffer concentration formulations (Res = resolubilized pellet). The figure shows the 34 
abundance of each peak as a percentage of the most abundant peak which was assigned a value of 35 
100%.  36 
 37 







Figure 1: (A) 7.5% non-reduced SDS-PAGE analysis of mAb samples in formulations 1-12, (B) 12% 5 
SDS-PAGE analysis of reduced mAb samples in formulations 1-12. Key: R stands for resolubilized 6 
sample in 8 M urea solution, Std is the standard mAb before formulation.  7 
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Figure 2: Size exclusion chromatography analysis of mAb samples after incubation in various 4 
formulations. (A) standard antibody, (B) formulation 1R, (C) formulation 2, (D) formulation 4, (E) 5 
formulation 8R, (F) formulation 9, (G) formulation 10, (H) formulation 12R. The chromatograph 6 
shown of formulation 1R (B) and 12R (H) shows that there was only a very small amount of protein 7 
in solution. Key: R stands for resolubilized sample in 8 M urea solution.  8 
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Figure 3: The % of each of the four major peaks observed by SEC-HPLC analysis of mAb samples 4 
in different formulations 1-12. RES = resolubilized sample in 8 M urea solution. All values 5 










Figure 4. (A) Fluorescence curves of high concentration mAb samples in formulations 1, 4, 8, 9, 3 
10 and 12 after incubation along with a standard MAb sample or comparison (n=3). The 4 
wavelength at which maximum intensity was observed was approximately 336 nm for all samples 5 
except formulation 1, 8 and 12 ǁŚĞƌĞďǇƚŚĞʄmax was shifted to 344, 339 and 346 nm respectively. 6 
(B) Denaturation curves for mAb in standard solution PBS, mAb in Formulation 4, mAb in 7 
formulation 9, mAb in formulation 10.  8 
 9 







Figure 5: (A) Heavy (HC) and (B) Light chain (LC) mass analysis of mAb samples after incubation in 5 
high concentration formulations 4, 9 and 10 by ESI-MS. The figure shows the abundance of each 6 
peak as a percentage of the most abundant peak which was assigned a value of 100%. 7 




Figure 6: Dose response curves for the mAb in formulations 4, 9 and 10. (A) mAb in formulation 4 2 
(B), mAb in formulation 9 and (C) mAb in formulation 10. The table shows the reference potency 3 
to the mAb STD. There was no significant change in the activity of the mAb after incubation in 4 
these formulations although in formulation 4 the potency was slightly elevated and in formulation 5 
10 slightly reduced. 6 
 7 





Figure 7: Mass analysis of ScFv samples after incubation in PBS and 100 mM, 250 mM and 500 3 
mM buffer concentration formulations (Res = resolubilized pellet). The figure shows the 4 
abundance of each peak as a percentage of the most abundant peak which was assigned a value of 5 
100%.  6 
 7 
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Supplementary Table S1. Variables investigated and the low/high amounts of each during Plackett-1 
Burman Design analysis 2 
Variables For lysozyme High level of variable Low level of variable 
Protein conc. (mM) 0.61 and 0.81 (mAb/ScFv) 0.070 
pH 8.5* 4* 
Buffer conc. (mM) 500 10 
Time (h) 168 2 
Temperature (°C) 55 4 
Glycine (M) 0.4 0.07 
NaCl (M) 0.25 0.05 





Supplementary Table S2. The Plackett-Burman seven variable factor design used to investigate the effects 8 















1 High High High High High High High 
2 Low High Low High High High Low 
3 Low Low High Low High High High 
4 High Low Low High Low High High 
5 Low High Low Low High Low High 
6 Low Low High Low Low High Low 
7 Low Low Low High Low Low High 
8 High Low Low Low High Low Low 
9 High High Low Low Low High Low 
10 High High High Low Low Low High 
11 Low High High High Low Low Low 
12 High Low High High High Low Low 
 10 
 11 
  12 
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Supplementary Table S3: Determination of the model mAb concentration in solution upon formulation 1 
and after incubation in formulations 1-12 by A280 nm measurement. The percentage in solution after 2 


















STD high*  
116.00 116.00 0.00 100 0 
1 (high) 111.11 2.05 0.01 2 98 
2 (low) 9.80 7.92 0.52 81 19 
3 (low) 9.72 0.29 0.02 3 97 
4 (high) 110.83 105.89 1.57 96 4 
5 (low) 10.97 11.13 0.17 101 -1 
6 (low) 10.95 10.85 0.11 99 1 
7 (low) 10.00 9.87 0.20 99 1 
8 (high) 110.83 0.46 0.15 0 100 
9 (high) 107.69 104.27 0.75 97 3 
10 (high) 110.26 109.40 1.73 99 1 
11 (low) 10.17 10.14 0.06 100 0 
12 (high) 60.11 0.53 0.46 1 99 
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Supplementary Table S4: Statistical analysis of the effect of formulation variables on mAb loss 1 
(precipitation) as determined by A280 analysis. The statistical significance of changes in protein 2 
concentration (mg/ml) and % change amounts relative to a PBS control for each variable are shown upon 3 
formulation and after incubation. 4 




Upon Formulation After Incubation 
 
mg/ml % mg/ml % 
Protein conc. 
(mg/ml) 
P 0.496 0.431 0.086 0.271 
d.o.f 5 5 5 9 
 
% sign. 50.4 56.9 91.4 72.9 
Buffer comp. 
(mM) 
p 0.375 0.404 0.724 0.321 
d.o.f 5 5 9 9 
 
% sign. 62.5 59.6 27.6 67.9 
pH p 0.377 0.375 0.673 0.286 
 
D.F. 5 5 9 9 
 
% sign. 62.3 62.5 32.7 71.4 
Temp. (°C) p - - 0.082 0.017 
 
d.o.f - - 5 5 
 
% sign. - - 91.8 98.3 
Time (hours) p - - 0.757 0.899 
 
d.o.f - - 9 9 
 
% sign. - - 24.3 10.1 
Glycine (mg/ml) 
p 0.375 0.461 0.804 0.894 
d.o.f 5 5 9 9 
 
% sign. 62.5 53.9 19.6 10.6 
NaCl (M) p 0.324 0.367 0.759 0.901 
 
d.o.f 5 5 9 9 
 
% sign. 67.6 63.3 24.1 9.9 
Key: d.o.f. = degrees of freedom, % sign. = level of statistical significance, P= p value from two-tailed student 5 
t-test. 6 
 7 
